News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Bids Adieu to Oral Insulin, Shakes Up R&D for Growth



11/1/2016 6:18:45 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Novo Nordisk's new CEO won’t start till the New Year. But he’s already jumping in to reshape the company’s R&D priorities. The diabetes giant has opted to end its development of an oral form of insulin, which has long been an unattainable dream for the industry.

It’s also refocusing its pipeline to rely more upon in-licensing early stage projects and working with external academic collaborators.

Read at FierceBiotech


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES